{
    "clinical_study": {
        "@rank": "102555", 
        "arm_group": {
            "arm_group_label": "ASP7374 group", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate safety and immunogenicity of intramuscular ASP7374\n      in adults \u226561 years of age."
        }, 
        "brief_title": "A Study to Evaluate Intramuscular ASP7374", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Influenza", 
            "Vaccine"
        ], 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy or medically stable, as judged on the basis of history and concurrent\n             diseases.\n\n          -  Subject understands procedure of the protocol and is willing to comply with the\n             protocol.\n\n          -  Written informed consent has been obtained.\n\n        Exclusion Criteria:\n\n          -  Scheduled to receive another vaccine during the study.\n\n          -  Received influenza HA vaccine within 180 days prior to screening.\n\n          -  Received or scheduled to receive a live vaccine within 28 days prior to vaccination\n             with the study vaccine, and received or scheduled to receive an inactivated vaccine\n             or a toxoid within 7 days prior to vaccination with the study vaccine.\n\n          -  Diagnosis of immune deficit in the past, has a family member (within the third degree\n             of kinship) with a diagnosis of congenital immunodeficiency syndrome.\n\n          -  Received one of the following medications or treatment prior to vaccination with the\n             study vaccine: Interferon formulation, Drugs which affect the immune system,\n             corticosteroids, G-CSF, M-CSF, Human immunoglobulin products, Blood products, Blood\n             transfusion\n\n          -  History of anaphylactic shock or an allergic reaction such as generalized eruption\n             due to food or drug (including vaccines) allergies, fever \u226539.0\u00b0C within 2 days after\n             the previous vaccination (influenza vaccine and others)\n\n          -  History of seizures, except for febrile seizures in childhood"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "61 Years"
        }, 
        "enrollment": {
            "#text": "55", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01961960", 
            "org_study_id": "7374-CL-0105"
        }, 
        "intervention": {
            "arm_group_label": "ASP7374 group", 
            "description": "intramuscular", 
            "intervention_name": "ASP7374", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ASP7374", 
            "Prevention of seasonal influenza"
        ], 
        "lastchanged_date": "November 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kanto", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 3 Study of ASP7374 \uff0dOpen-label Study of Intramuscular ASP7374 in Adults \u226561 Years of Age\uff0d", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "evaluated for A/H1N1, A/H3N2, and B", 
            "measure": "hemagglutination inhibition (HI) antibody titer", 
            "safety_issue": "No", 
            "time_frame": "Day 1 and Day 29"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01961960"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "evaluated for A/H1N1, A/H3N2, and B", 
                "measure": "neutralizing antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 29"
            }, 
            {
                "measure": "Local and systemic reactions associated with the vaccination", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 8"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "UMN Pharma Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}